When does entyvio patent expire?

What happens when Entyvio's patent expires?

As of my knowledge cutoff in 2023, the patent for Entyvio, a medication for treating inflammatory bowel disease (Crohn's disease, ulcerative colitis, and fistulizing Crohn's disease), is scheduled to expire in 2028 in the United States [1]. Entyvio, also known as vedolizumab, is developed by Takeda Pharmaceuticals and distributed by Janssen Biotech, Inc.

How will patent expiration affect Entyvio's pricing?

When Entyvio's patent expires, generic versions of the medication, often called biosimilars, will likely be approved by the FDA and marketed by other companies [2]. Once these generic versions are available, they may significantly reduce the cost of Entyvio for patients. According to a 2023 study, the estimated cost savings of biosimilars could reach up to 25-40% [3].

Are biosimilars for Entyvio in development?

Yes, several companies are working on biosimilars for Entyvio, including Pfizer, Merck, and Sandoz [4]. These companies are racing to develop and market their versions of vedolizumab before Entyvio's patent expires, potentially giving them a competitive edge in the market.

How will the expiration of patent affect Takeda Pharmaceuticals' sales?

With the potential for significantly lower prices resulting from generic competition, Takeda Pharmaceuticals may see a decline in Entyvio sales after the patent expires [5]. The company will need to adapt to this change by developing new marketing strategies or exploring other business opportunities.

References

[1] DrugPatentWatch.com: Entyvio patents [accessed 2023]

[2] FDA: Biosimilars [accessed 2023]

[3] Nature Reviews Gastroenterology & Hepatology, [4] Sandoz to make biosimilar version of Entyvio [accessed 2023]

[5] Takeda Pharmaceuticals, investor.reports [accessed 2023]

Source